|
|||||
|
|
Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia |
|
| Authors: | Oliver Birke Aaron Schindeler Manoj Ramachandran Chris T. Cowell Craig F. Munns Michael Bellemore David G. Little |
| Affiliation: | (1) Orthopaedic Research and Biotechnology Unit, The Children’s Hospital at Westmead, Westmead, Australia;(2) Department of Orthopaedics, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW, 2145, Australia;(3) Discipline of Paediatrics and Child Health, Faculty of Medicine, University of Sydney, Sydney, Australia;(4) Department of Orthopaedics and Trauma, The Royal London Hospital, Barts and The London NHS Trust, London, UK;(5) Department of Endocrinology and Diabetes, The Children’s Hospital at Westmead, Westmead, Australia |
| Abstract: | PurposeCongenital pseudarthrosis of the tibia (CPT) is a rare but serious disorder in children. No single approach has clearly emerged as superior in terms of operative procedure, fixation, optimal time for surgery or adjunctive pharmaceutical intervention. CPT is frequently associated with neurofibromatosis type 1 (NF1), a condition featuring deficient bone anabolism and excessive catabolism. We have therefore combined the use of bone morphogenetic proteins (BMP) with bisphosphonates (BP) as an adjunct to surgical intervention. |
| Keywords: | Congenital pseudarthrosis of the tibia Neurofibromatosis type 1 NF1 Bone morphogenetic protein Bisphosphonate |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |